<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808352</url>
  </required_header>
  <id_info>
    <org_study_id>HPTN 073</org_study_id>
    <nct_id>NCT01808352</nct_id>
  </id_info>
  <brief_title>HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)</brief_title>
  <official_title>Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HIV Prevention Trials Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HIV Prevention Trials Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Black men who have sex with men (MSM) Pre-Exposure Prophylaxis (PrEP) Study with Client&#xD;
      Centered Care Coordination (C4)Component.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label demonstration study with PrEP and Client Centered Care Coordination (C4) to&#xD;
      assess the initiation, acceptability, safety, and feasibility of PrEP for Black MSM (BMSM) in&#xD;
      three US Cities. A subset of participants will also be recruited to participate in&#xD;
      qualitative interviews about facilitators and barriers regarding PrEP. The study will recruit&#xD;
      HIV-uninfected BMSM at risk for HIV infection in three US Cities. Enrollment will include&#xD;
      those aged 18 and over with an effort to recruit an equal number of BMSM under age 25 and&#xD;
      over age 25 with a total of 225 participants (75 per site).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initiation of PrEP</measure>
    <time_frame>30 months</time_frame>
    <description>Documented in either study CRFs or ACASI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to PrEP</measure>
    <time_frame>30 months</time_frame>
    <description>Adherence will be assessed via self-report (ACASI), PBMCs and plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 months</time_frame>
    <description>Graded via DAIDS Toxicity Grading System determined by review of reported adverse events (clinical and laboratory)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STIs</measure>
    <time_frame>30 months</time_frame>
    <description>Rectal and urine GC/CT, and NAAT for syphilis and chlamydia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sexual risk-taking behavior</measure>
    <time_frame>30 months</time_frame>
    <description>Measured by ACASI assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiate or decline PrEP</measure>
    <time_frame>30 months</time_frame>
    <description>Refusal rates will be measured by ACASI assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident HIV-seroconversions/characteristics</measure>
    <time_frame>30 months</time_frame>
    <description>HIV RNA and genotyping will be performed at the NL on samples confirmed to be HIV infected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant perception of care and referral plan</measure>
    <time_frame>30 months</time_frame>
    <description>Assessed via interviewer-administered questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Daily PrEP + coordination of client centered svs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF</intervention_name>
    <description>All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.</description>
    <arm_group_label>Daily PrEP + coordination of client centered svs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        BMSM who meet all of the following criteria are eligible for inclusion in this study:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  No prior HIV diagnosis (self-report)&#xD;
&#xD;
          -  Male at birth&#xD;
&#xD;
          -  High risk for acquiring HIV infection including any one of the following in the&#xD;
             previous 6 months:&#xD;
&#xD;
               -  Unprotected sex during receptive or insertive anal intercourse with a male&#xD;
                  partner&#xD;
&#xD;
               -  Any protected or unprotected:&#xD;
&#xD;
                  i. Receptive or insertive anal intercourse with more than three male sex partners&#xD;
                  ii. Exchange of money, gifts, shelter or drugs for receptive or insertive anal&#xD;
                  sex with a male partner iii. Receptive or insertive anal sex while under the&#xD;
                  influence of drugs or alcohol (i.e., high or drunk within two hours of the sex&#xD;
                  act) according to self-report&quot;&#xD;
&#xD;
               -  STI diagnosis (i.e., syphilis, gonorrhea and chlamydia) by self-report&#xD;
&#xD;
          -  Willing to provide locator information in accordance with the Study Specific&#xD;
             Procedures (SSP) Manual&#xD;
&#xD;
          -  Urine dipstick negative or trace for protein and glucose&#xD;
&#xD;
          -  Hemoglobin &gt; 11 g/dL, absolute neutrophil count &gt; 750 cells/mm3, and platelet count â‰¥&#xD;
             100,000/mm3&#xD;
&#xD;
          -  Serum creatinine &lt; upper limit of normal (ULN) and calculated creatinine clearance of&#xD;
             at least 60 mL/min by the Cockcroft-Gault formula where:&#xD;
&#xD;
             o eCcr in mL/min = [(140 - age in years) x (actual body weight in kg)] / (72 x serum&#xD;
             creatinine in mg/dL) Alanine aminotransferase (AST) and aspartate aminotransferase&#xD;
             (ALT) &lt; 3 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &lt; 2.5 ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        BMSM who meet any of the following criteria will be excluded from this study:&#xD;
&#xD;
          -  Any reactive or positive HIV test at Screening, even if subsequent testing indicates&#xD;
             that the person is HIV-uninfected&#xD;
&#xD;
          -  Transgender&#xD;
&#xD;
          -  Active or chronic hepatitis B infection (as evidenced by HBsAg, HbsAb, and HbcAb&#xD;
             testing)&#xD;
&#xD;
          -  Planning to move out of the area or to travel for more than 3 months during the study&#xD;
             follow-up period&#xD;
&#xD;
          -  Unwilling to adhere to study procedures&#xD;
&#xD;
          -  Current participation in any research study via self-report (however, strictly non-HIV&#xD;
             centered observational studies are not exclusionary)&#xD;
&#xD;
          -  Previous participation in an HIV vaccine study is exclusionary unless documented&#xD;
             evidence of enrollment into a placebo arm&#xD;
&#xD;
          -  Use of ARV drugs (PrEP or PEP) in the last 60 days&#xD;
&#xD;
          -  Prior history of a gastrectomy, colostomy, ileostomy, or any other procedure altering&#xD;
             the gastrointestinal tract or drug absorption (provided by self-report, or obtained&#xD;
             from medical history or records)&#xD;
&#xD;
          -  Receipt of prohibited medications: interleukin therapy, medications with significant&#xD;
             nephrotoxic potential (including but not limited to amphotericin B, aminoglycosides,&#xD;
             cidofovir, foscarnet and systemic chemotherapy), and medications that may inhibit or&#xD;
             compete for elimination via active renal tubular secretion (including but not limited&#xD;
             to probenecid) - (provided by self-report, or obtained from medical history or medical&#xD;
             records)&#xD;
&#xD;
          -  Any condition, that in the opinion of study staff, would make participation in the&#xD;
             study unsafe, or interfere with achieving the study objective&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Shoptaw, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Vice Street Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manya Magnus, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Hightow-Weidman</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Vine Street Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AE adverse event</keyword>
  <keyword>AIDS acquired immunodeficiency syndrome</keyword>
  <keyword>ALT (SGPT) alanine aminotransferase</keyword>
  <keyword>ART antiretroviral therapy</keyword>
  <keyword>AST (SGOT) aspartate aminotransferase</keyword>
  <keyword>DCF data collection forms</keyword>
  <keyword>DMC Data Monitoring Committee</keyword>
  <keyword>FDA (U.S.) Food and Drug Administration</keyword>
  <keyword>GCP Good Clinical Practice guidelines</keyword>
  <keyword>HB sAg Hepatitis B surface antigen</keyword>
  <keyword>ICH International Conference of Harmonisation</keyword>
  <keyword>IND Investigational New Drug Application</keyword>
  <keyword>IRB Institutional Review Board</keyword>
  <keyword>IU International units</keyword>
  <keyword>mg milligram(s)</keyword>
  <keyword>mm3 cubic millimeter(s)</keyword>
  <keyword>PCR polymerase chain reaction</keyword>
  <keyword>SAE serious adverse event</keyword>
  <keyword>Âµg microgram</keyword>
  <keyword>ULN upper limit of the normal range</keyword>
  <keyword>WB Western Blot</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 13, 2020</submitted>
    <returned>December 8, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

